Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets

Table 8

Experimental design batches for FDC ODTs with response parameters (mean ± SD).

Formulation code	Responses
	Friability (%)	Disintegration time (seconds)
Fd1	0.65 ± 0.02	64 ± 1.78
Fd2	0.28 ± 0.01	26 ± 0.89
Fd3	0.98 ± 0.03	53 ± 2.68
Fd4	0.26 ± 0.02	34 ± 1.78
Fd5	0.47 ± 0.00	73 ± 1.57
Fd6	0.51 ± 0.01	19 ± 0.80
Fd7	1.21 ± 0.13	11 ± 0.89
Fd8	0.36 ± 0.01	84 ± 2.68
Fd9	1.13 ± 0.11	13 ± 0.88
Fd10	0.18 ± 0.00	93 ± 3.57
Fd11	0.23 ± 0.00	14 ± 0.89
Fd12	0.30 ± 0.00	35 ± 0.78
Fd13	0.16 ± 0.00	42 ± 1.78
Fd14	0.15 ± 0.00	102 ± 2.68
Fd15	0.20 ± 0.00	109 ± 4.47
Fd16	0.68 ± 0.03	16 ± 0.82
Fd17	0.35 ± 0.01	49 ± 0.68
Fd18	0.31 ± 0.00	33 ± 1.78
Fd19	0.51 ± 0.01	23 ± 0.89

Fd = formulation design based on the CCD.